Individual differences in cognitive decline during normal aging and Alzheimer's disease (AD) are common, but the molecular mechanisms underlying these distinct outcomes are not fully understood. We utilized a combination of genetic, molecular, and behavioral data from a mouse population designed to model human variation in cognitive outcomes to search for the molecular mechanisms behind this population-wide variation. Specifically, we used a systems genetics approach to relate gene expression to cognitive outcomes during AD and normal aging. Statistical causal-inference Bayesian modeling was used to model systematic genetic perturbations matched with cognitive data that identified astrocyte and microglia molecular networks as drivers of cognitive resilience to AD. Using genetic mapping, we identifiedFgf2as a potential regulator of the astrocyte network associated with individual differences in short-term memory. We also identified several immune genes as regulators of a microglia network associated with individual differences in long-term memory, which was partly mediated by amyloid burden. Finally, significant overlap between mouse and two different human coexpression networks provided strong evidence of translational relevance for the genetically diverse AD-BXD panel as a model of late-onset AD. Together, this work identified two candidate molecular pathways enriched for microglia and astrocyte genes that serve as causal AD cognitive biomarkers, and provided a greater understanding of processes that modulate individual and population-wide differences in cognitive outcomes during AD.
Diverse cellular states have been mapped in Alzheimer’s disease (AD) pathology, but their links to cognitive decline and the tissue signals driving their emergence remain unclear. We assembled a unified single-nucleus atlas from 867 diverse brains. Meta-analysis identified new cell-state associations with AD and prioritized a non-canonical reactive
SLC38A2
high
SMTN
high
CACNA1D
high astrocyte (Ast10) as a key link between neuropathologies and cognitive decline. To identify regulators of Ast10 emergence, we modeled ligand-receptor relationships. Independent datasets and two spatial modalities validated these drivers and revealed Ast10’s multifocal distribution throughout the neocortex. Mechanistic validation in mouse and human astrocytes confirmed PLXNB1 , JAM2 and SEMA4D as regulators. In cerebrospinal fluid from a SEMA4D-blocking antibody trial, Ast10 markers are pharmacologically modifiable, and their reduction tracks with cognitive stabilization. Ast10 may contribute to cognitive decline through disrupted presynaptic neurotransmitter release and may be a convergence point for AD and other neurodegenerative pathologies, a promising target for enhancing resilience to dementia.
INTRODUCTION: Human data suggest susceptibility and resilience to features of Alzheimer's disease (AD) such as microglia activation and synaptic dysfunction are under genetic control. However, causal relationships between these processes, and how genomic diversity modulates them remain systemically underexplored in mouse models.METHODS: AD‐vulnerable hippocampal neurons were virally labeled in inbred (C57BL/6J) and wild‐derived (PWK/PhJ) APP/PS1 and wild‐type mice, and brain microglia depleted from 4 to 8 months of age. Dendrites were assessed for synapse plasticity changes by evaluating spine densities and morphologies.RESULTS: In C57BL/6J, microglia depletion blocked amyloid‐induced synaptic density and morphology changes. At a finer scale, synaptic morphology on individual branches was dependent on microglia–dendrite physical interactions. Conversely, synapses from PWK/PhJ mice showed remarkable stability in response to amyloid, and no evidence of microglia contact‐dependent changes on dendrites.DISCUSSION: These results demonstrate that microglia‐dependent synaptic alterations in specific AD‐vulnerable projection pathways are differentially controlled by genetic context.
Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune inflammatory disease with genomic and non-genomic contributions to risk. We hypothesize that epigenetic factors are a significant contributor to SLE risk and may be informative for identifying pathogenic mechanisms and therapeutic targets. To test this hypothesis while controlling for genetic background, we performed an epigenome-wide analysis of DNA methylation in genomic DNA from whole blood in three pairs of female monozygotic (MZ) twins of European ancestry, discordant for SLE. Results were replicated on the same array in four cell types from a set of four Danish female MZ twin pairs discordant for SLE. Genes implicated by the epigenetic analyses were then evaluated in 10 independent SLE gene expression datasets from the Gene Expression Omnibus (GEO). There were 59 differentially methylated loci between unaffected and affected MZ twins in whole blood, including 11 novel loci. All but two of these loci were hypomethylated in the SLE twins relative to the unaffected twins. The genes harboring these hypomethylated loci exhibited increased expression in multiple independent datasets of SLE patients. This pattern was largely consistent regardless of disease activity, cell type, or renal tissue type. The genes proximal to CpGs exhibiting differential methylation (DM) in the SLE-discordant MZ twins and exhibiting differential expression (DE) in independent SLE GEO cohorts (DM-DE genes) clustered into two pathways: the nucleic acid-sensing pathway and the type I interferon pathway. The DM-DE genes were also informatically queried for potential gene–drug interactions, yielding a list of 41 drugs including a known SLE therapy. The DM-DE genes delineate two important biologic pathways that are not only reflective of the heterogeneity of SLE but may also correlate with distinct IFN responses that depend on the source, type, and location of nucleic acid molecules and the activated receptors in individual patients. Cell- and tissue-specific analyses will be critical to the understanding of genetic factors dysregulating the nucleic acid-sensing and IFN pathways and whether these factors could be appropriate targets for therapeutic intervention.
The disconnection of neuronal circuitry through synaptic loss is presumed to be a major driver of age‐related cognitive decline. Age‐related cognitive decline is heterogeneous, yet whether genetic mechanisms differentiate successful from unsuccessful cognitive decline through maintenance or vulnerability of synaptic connections remains unknown. Previous work using rodent and primate models leveraged various techniques to imply that age‐related synaptic loss is widespread on pyramidal cells in prefrontal cortex (PFC) circuits but absent on those in area CA1 of the hippocampus. Here, we examined the effect of aging on synapses on projection neurons forming a hippocampal‐cortico‐thalamic circuit important for spatial working memory tasks from two genetically distinct mouse strains that exhibit susceptibility (C57BL/6J) or resistance (PWK/PhJ) to cognitive decline during aging. Across both strains, synapse density on CA1‐to‐PFC projection neurons appeared completely intact with age. In contrast, we found synapse loss on PFC‐to‐nucleus reuniens (RE) projection neurons from aged C57BL/6J but not PWK/PhJ mice. Moreover, synapses from aged PWK/PhJ mice but not from C57BL/6J exhibited altered morphologies that suggest increased efficiency to drive depolarization in the parent dendrite. Our findings suggest resistance to age‐related cognitive decline results in part by age‐related synaptic adaptations, and identification of these mechanisms in PWK/PhJ mice could uncover new therapeutic targets for promoting successful cognitive aging and extending human health span.
INPP5D , which encodes SHIP1, is genetically associated with Alzheimer’s disease (AD) risk and regulates microglial immune function. Here we identified SHIP1 as a regulator of endo-lysosomal homeostasis in human microglia. INPP5D haploinsufficiency impaired endosome maturation and lysosomal degradation, leading to lipid droplet accumulation, lysosomal stress, and NLRP3 inflammasome activation. SHIP1-deficient microglia shifted from an immune-responsive state toward a disease-associated state with elevated cargo-selective phagocytosis. Although amyloid-β uptake was unaffected, SHIP1-deficient microglia accumulated intracellular amyloid-β and exhibited exacerbated lipid droplet accumulation, consistent with defective lysosomal processing. Proteomic analysis of genetically diverse human microglia revealed that the protective INPP5D rs10933431 variant is associated with elevated phosphatase-domain containing SHIP1, and protein profiles consistent with enhanced endolysosomal trafficking. In mice xenografted with SHIP1-deficient human microglia, high amyloid-β burden exacerbated lysosomal, lipid droplet and inflammasome phenotypes. Together, these findings identify disrupted endo-lysosomal trafficking and degradative capacity as mechanisms linking INPP5D dysfunction to disease-associated microglial states in AD.